Analytical Data
-
Gene name
GBP6
- Application
-
Alternative Names
GTP-binding protein 6; Guanine nucleotide-binding protein 6
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6ZN66
-
Expression Region
Ser35~Arg277
-
Molecular Weight
32kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GBP6, or Guanylate Binding Protein 6, is a member of the guanylate-binding protein family, which plays a critical role in the host's immune response to various pathogens, particularly viruses. This family of proteins is characterized by their ability to bind guanosine triphosphate (GTP) and is known to be involved in intracellular signaling and regulation of inflammatory responses. Research into GBP6 has gained momentum due to its potential implications in understanding the mechanisms of host defense and pathology related to infectious diseases and autoimmune disorders. Studies have shown that GBP6 can be activated by interferons and is essential for the formation of immune complexes that facilitate the clearance of intracellular pathogens. Moreover, its expression levels and activity have been correlated with disease severity in various models, making it a promising candidate for therapeutic targeting. The structural characterization of GBP6 is crucial for elucidating its functional mechanisms, which could pave the way for novel interventions in diseases where the immune response is dysregulated. As research continues, GBP6 is emerging as a significant player in innate immunity, prompting further investigation into its role in health and disease, as well as its potential as a biomarker for inflammatory conditions and infections.
